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ABSTRACT
Objectives To review evidence supporting use of
fluoroquinolones as first line agents over other antibiotics
for treating typhoid and paratyphoid fever (enteric fever).
Design Meta-analysis of randomised controlled trials.
Data sources Cochrane Infectious Diseases Group
specialised register, CENTRAL (issue 4, 2007), Medline
(1966-2007), Embase (1974-2007), LILACS (1982-2007),
selected conferences, reference lists, and ongoing trial
register (November 2007).
Review methods Trials comparing fluoroquinolones with
chloramphenicol, cephalosporins, or azithromycin in
culture-proven enteric fever were included. Two reviewers
extracted data and assessed methodological quality.
Odds ratios with 95% confidence intervals were
estimated. Trials recruiting over 60% children were
analysed separately from trials on adults. Primary
outcomes studied were clinical failure, microbiological
failure, and relapse.
Results Twenty trials were included. Trials were small and
often of limited methodological quality. Only 10 trials
concealed allocation and only three were blinded. In trials
on adults, fluoroquinolones were not significantly
different from chloramphenicol for clinical failure (594
participants) or microbiological failure (n=378), but
reduced clinical relapse (odds ratio 0.14 (95% confidence
interval 0.04 to 0.50), n=467, 6 trials). Azithromycin and
fluoroquinolones were comparable (n=152, 2 trials).
Compared with ceftriaxone, fluoroquinolones reduced
clinical failure (0.08 (0.01 to 0.45), n=120, 3 trials) but
not microbiological failure or relapse. Compared with
cefixime, fluoroquinolones reduced clinical failure (0.05
(0.01 to 0.24), n=238, 2 trials) and relapse (0.18 (0.03 to
0.91), n=218, 2 trials). In trials on children infected with
nalidixic acid resistant strains, older fluoroquinolones
(ofloxacin) produced more clinical failures than
azithromycin (2.67 (1.16 to 6.11), n=125, 1 trial), but
there were no differences with newer fluoroquinolones
(gatifloxacin, n=285, 1 trial). Fluoroquinolones and
cefixime were not significantly different (n=82, 1 trial).
Conclusions In adults, fluoroquinolones may be better
than chloramphenicol for preventing clinical relapse.
Data were limited for other comparisons, particularly for
children.

INTRODUCTION
Enteric fever (typhoid or paratyphoid fever) caused by
Salmonella serotype Typhi (S Typhi) or Salmonella serotype Paratyphi (S Paratyphi) remains endemic in
many areas of the developing world, causing over 26
million infections and over 200 000 deaths annually.1
The incidence is highest in south-central Asia and
South East Asia (over 100/100 000 cases/year),1 with
the highest burden of disease in children aged
2-15 years.2-9S Typhi represents the commonest cause
of bacteraemia in this age group,4 6 and annual typhoid
rates (confirmed by blood culture) in recent studies
from India, Pakistan, and Indonesia range from 149
to as high as 573 cases per 100 000 children.9 Other
regions contributing to global morbidity and mortality
include Africa, Latin America, the Caribbean, and
other parts of Asia.1
Fluoroquinolones are recommended as first line
therapy for children and adults infected with sensitive
as well as multidrug resistant (resistant to all three first
line inexpensive antibiotics, chloramphenicol, amoxicillin, and co-trimoxazole) S Typhi and Paratyphi.10 A
summary11 of randomised controlled trials of enteric
fever concluded that fluoroquinolones had lower clinical failures and shorter fever clearance times compared with first line antibiotics and ceftriaxone and
cefixime. However, few trials enrolled children,12 and
a meta-analysis was not conducted.
The recommendation to use fluoroquinolones as
first line therapy for enteric fever, particularly in children, irrespective of sensitivity patterns—and without
a thorough analysis and assessment of quality of evidence—has had profound public health implications
for developing countries. These range from increasing
costs of treatment to alarming rates of drug resistance.
Strains of S Typhi and Paratyphi with reduced susceptibility to fluoroquinolones have rapidly emerged—
most displaying resistance to nalidixic acid and associated with poor response to treatment. 9 13-34 Even
more alarming are reports of high level fluoroquinolone resistance.25 29 30 32 34-38 Although newer generation
fluoroquinolones such as gatifloxacin are active against
nalidixic acid resistant strains,39 40 it may only be a
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matter of time before resistance to newer agents
becomes widespread if indiscriminate and inappropriate use of fluoroquinolones for any febrile illness continues in endemic areas.41

However, although antimicrobial resistance patterns
show wide regional variations,9 some reports suggest
that multidrug resistant strains of S Typhi have declined
from previously high figures,19 24 25 29 32 34 42-45 indicating

Characteristics and methodological quality of trials included in meta-analysis

Study

Country
and year of study
(if stated)

Participants’ age group,
setting, culture site, and
severity at enrollment*

No of participants
(in fluoroquinolone
group: other group)

Methodological
quality of trials†

Drug regimens
used‡

Fluoroquinolone versus chloramphenicol
Quintero 198863
(conference abstract)

Mexico

Adult dosages, inpatients,
blood culture, severity
unknown§

26 (13:13)

Randomisation unclear, allocation
concealment unclear, double
blinded, follow-up adequate

Ciprofloxacin 750 mg orally 3 times a
day. Chloramphenicol 750 mg orally 4
times a day. Duration not mentioned

Bran 199164 (conference
abstract)

Guatemala

Adult dosages, inpatients,
blood and/or bone marrow
culture, severity unknown§

102 (51: 51)§

Randomisation unclear, allocation
concealment unclear, double
blinded, follow-up adequate

Ciprofloxacin 500 mg orally twice a day
for 10 days. Chloramphenicol 750 mg
orally every 6 hours for 14 days

Gottuzzo 199265

—

Adult inpatients, mainly blood 98 (49:49)
culture, severity unknown§

Randomisation unclear, allocation
concealment unclear, double
blinded, follow-up adequate

Ciprofloxacin 500 mg orally every 12
hours for 10 days. Chloramphenicol
750 mg orally every 6 hours for 14 days

Morelli 199266

Italy 1985-90

Adult inpatients, blood
culture, severity unknown

156([30:36:20:20]:30)¶

Randomisation adequate,
allocation concealment unclear,
unblinded, follow-up adequate

Ofloxacin 300 mg, pefloxacin 400 mg,
ciprofloxacin 500 mg, enoxacin
300 mg (all orally every 8 hours for
15 days) Chloramphenicol 500 mg
orally every 6 hours for 15 days

Yousaf 199267

Pakistan 1989-92

Adult inpatients, blood
culture, severity unknown§

50 (25:25)

Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up inadequate

Ofloxacin 200 mg orally twice a day for
14 days. Chloramphenicol 50 mg/kg/
day orally, 30 mg/kg/day when
afebrile, for 14 days

Abejar 199368

Philippines

Adult inpatients, blood
culture, severity unknown

30 (15:15)

Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate

Fleroxacin 400 mg orally once a day for
10 days. Chloramphenicol 50 mg/kg/
day orally in 3 divided doses every 8
hours for 14 days

Arnold 199369

Multicentre: South
America,
Indonesia, etc§

Adult inpatients, blood
culture, no major
complications

91 ([24:33]:34)

Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate

Fleroxacin 400 mg orally once a day for
7 days. Fleroxacin 400 mg orally once a
day for 14 days. Chloramphenicol
50 mg/kg/day orally for 14 days

Cristiano 199570

Italy 1991-3

Adult inpatients, blood
culture, all severe cases

60 (30:30)

Randomisation adequate,
allocation concealment unclear,
unblinded, follow-up adequate

Pefloxacin 1200 mg IV in 3 divided
doses every 8 hours for 5 days then
orally for 10 days. Chloramphenicol 2 g
orally in 4 divided doses every 6 hours
for 15 days

Gasem 200371

Indonesia 1997

Adult inpatients, blood and/or 55 (28:27)
bone marrow culture, no
severe complications

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate

Ciprofloxacin 500 mg orally twice a day
for 7 days. Chloramphenicol 500 mg
orally four times a day for 14 days

Phongmany 200572**

Laos 2001-3

Adult inpatients, blood
culture, uncomplicated

50 (27:23)

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate

Ofloxacin 15 mg/kg/day orally in 2
divided doses for 3 days.
Chloramphenicol 50 mg/kg/day orally
in 4 divided doses for 14 days

Fluoroquinolone versus ceftriaxone
Wallace 199373

Bahrain

Adult inpatients, blood
culture, severity unknown

42 (20:22)

Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate

Ciprofloxacin 500 mg orally twice a day
for 7 days. Ceftriaxone 3 g/day IV for
7 days

Smith 199474**

Vietnam 1992-3

Adult inpatients, blood and/or 47 (22:25)
bone marrow (n=44) stool
(n=3) culture, uncomplicated

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate

Ofloxacin 200 mg orally every 12 hours
for 5 days. Ceftriaxone 3 g/day IV for
3 days

Tran 199475**

Vietnam 1992-3

Adult inpatients, blood
culture, uncomplicated

31 (16:15)

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate

Fleroxacin 400 mg orally once a day for
7 days. Ceftriaxone 2 g IV once daily for
5 days

Fluoroquinolone versus cefixime
Yu, 199876 (in Chinese)

China

Adult inpatients, blood or
bone marrow culture, severe
cases included§

80 (40:40)

Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate

Levofloxacin 200 mg orally twice a day
for 10 days. Cefixime 200 mg orally
twice a day for 10 days

Cao 199977**

Vietnam 1995-6

Child (<15 years old)
inpatients, blood culture,
uncomplicated

82 (38:44)

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate

Ofloxacin 10 mg/kg/day orally in 2
divided doses for 5 days. Cefixime
20 mg/kg/day orally in 2 divided
doses for 7 days

Pandit 200739**

Nepal 2005

Adult and child (35.5% < 14
years) outpatients, blood
culture, uncomplicated

158 (88:70)

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate

Gatifloxacin 10 mg/kg/day orally once
a day for 7 days. Cefixime 20 mg/kg/
day orally in 2 divided doses for 7 days
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Study

Country
and year of study
(if stated)

Participants’ age group,
setting, culture site, and
severity at enrollment*

No of participants
(in fluoroquinolone
group: other group)

Methodological
quality of trials†

Drug regimens
used‡

Fluoroquinolone versus azithromycin
Girgis 199978**

Egypt 1997-8

Adult inpatients, blood (n=62) 64 (28:36)
stool (n=2) culture,
uncomplicated

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate

Ciprofloxacin 500 mg orally twice a day
for 7 days. Azithromycin 1 g orally once
on day 1, then 500 mg once a day for
6 days (total of 7 days)

Chinh 200079**

Vietnam

Adult inpatients, blood
culture, uncomplicated

88 (44:44)

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate

Ofloxacin 200 mg orally twice a day
(8 mg/kg/day) for 5 days.
Azithromycin 1 g orally daily
(20 mg/kg/day) for 5 days

Parry 200780**

Vietnam
1998-2002

Adult and child (87% <15
years) inpatients, blood and/
or bone marrow culture,
uncomplicated††

125 (63:62)

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate

Ofloxacin 20 mg/kg/day orally in 2
divided doses for 7 days. Azithromycin
10 mg/kg/day orally once a day for
7 days

Dolecek 200840**

Vietnam
(3 hospitals)
2004-5

Adult and child (73% <15
years) inpatients, blood and/
or bone marrow culture,
uncomplicated

285 (145:140)

Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate

Gatifloxacin 10 mg/kg/day orally once
a day for 7 days. Azithromycin 20 mg/
kg/day orally once a day for 7 days

*Severity of fever at enrollment was as defined by trial investigators.
†Quality assessment as follows. Randomisation: adequate (methods such as computer generated random numbers or use of a random number table), inadequate (methods such as
assignment based on day of presentation or alternation), unclear (method not described). Allocation concealment: adequate (methods such as use of sealed envelopes), inadequate (such
as unsealed envelopes), unclear (no information provided). Blinding: single (either care provider/outcome assessor or participants were unaware of treatment), double (participants and care
provider/outcome assessor were unaware of treatment), open (all parties were aware of treatment). Follow-up: adequate (≥90% of participants with culture confirmed infection followed up),
inadequate (<90% of such participants followed up).
‡For trials that compared different fluoroquinolones (such as ofloxacin and ciprofloxacin) or different durations of fluoroquinolones (such as 7 and 14 days), we combined all
fluoroquinolone groups for comparison with groups receiving the non-fluoroquinolone antibiotic.
§Some information not explicitly stated, but assumed based on information in trial.
¶The norfloxacin group was not included in this meta-analysis (see text for explanation).
**Author provided additional information.
††A third arm in this study, involving combination of treatments, was not included in this meta-analysis

that chloramphenicol could still be used in some endemic areas. On the other hand multidrug resistant strains
of S Paratyphi may be emerging,24 29 46 47 which underscores the complexities of treatment and limited alternatives available.48
This meta-analysis was undertaken to determine the
strength of evidence supporting use of fluoroquinolones over chloramphenicol, ceftriaxone, cefixime,
and azithromycin for treating enteric fever in children
and adults.49
METHODS
Search strategy and selection criteria
We searched the Cochrane Infectious Diseases
Group’s specialised register (November 2007),
Cochrane central register of controlled trials (CENTRAL, issue 4, 2007), Medline (1966 to November
2007), Embase (1974 to November 2007), and
LILACS (1982 to November 2007) using text words
and medical subject headings (MeSH) “typhoid
fever,” “enteric fever,” “paratyphoid fever,” “Salmonella Typhi,” “Salmonella Paratyphi” combined with
the Cochrane Collaboration’s search strategy.50 A
complete list of search terms used is available.49 We
identified relevant trials in all languages, searched
selected conference proceedings, authors’ files, reference lists, and the meta-Register of Controlled Trials
(mRCT), and contacted experts for relevant ongoing
or unpublished trials.49
One reviewer screened titles and abstracts, and
potentially relevant trials were further evaluated independently by two reviewers using pre-designed eligibility forms. Trials were included if they were
BMJ | ONLINE FIRST | bmj.com

randomised and compared fluoroquinolone with
another antibiotic in enteric fever confirmed with
blood or bone marrow culture.
Data abstraction and methodological assessment

Two reviewers independently extracted data using
piloted data extraction forms, compared data, and
resolved disagreements. Primary outcomes (measured
at time points described by investigators) were clinical
failure (presence of symptoms or development of complications necessitating change in or prolongation of
antibiotic therapy), microbiological failure (positive
culture from blood, bone marrow, or any sterile anatomical site), and relapse (recurrence of symptoms with a
positive culture from blood, bone marrow, or any sterile anatomical site). Secondary outcomes included
fever clearance time (time taken in hours from the
start of therapy to defervescence, as defined by
authors), convalescent faecal carriage (positive faecal
culture detected at any time after end of treatment up
to one year of follow-up), cost of therapy, length of
hospitalisation, complications, and adverse events.49
We contacted study authors for additional data or to
clarify data.
Two reviewers independently assessed methodological quality of trials based on the method of randomisation (generation of allocation sequence), allocation
concealment, blinding, and follow-up of participants
with culture-proven enteric fever (see table). 49 51 We
conducted an available case analysis and derived the
proportion of participants lost to follow-up at final
outcome.
page 3 of 11
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Statistical analysis and stratifications
We conducted meta-analyses using Review Manager
5,52 with odds ratios for dichotomous data and mean
differences for continuous data, presented with 95%
confidence intervals. We used Mantel-Haenszel odds
ratios since there were limited data and few trials.53
Because the events are relatively rare, the estimated
odds ratios can be considered similar to risk ratios.53
We did not combine trials recruiting children (trials
with >60% participants who were <16 years) with trials
recruiting adults (≥16 years or “adults” as described by
the investigators), since enteric fever differs in severity,
clinical manifestations, and outcome in children and
adults,54-57 and because of generic differences in drug
pharmacokinetics and pharmacodynamics in children
and adults. Adverse events from fluoroquinolones are
still not clearly delineated in children.58 59 We stratified
results by presence of multidrug resistant strains (for trials
involving chloramphenicol) and nalidixic acid resistant
strains (all trials). (All stratifications are presented
elsewhere.49) We generated a funnel plot to assess publication bias for comparisons with more than five trials. We
assessed heterogeneity by visual inspection of graphs and
χ2 test for homogeneity (at 10% level of significance) and
explained heterogeneity by exploring differences in drug
doses or durations, severity of enteric fever (as defined by
investigators), and time points of outcome measurement.
We used a fixed effects model to pool data. When we
found significant heterogeneity we used a random effects
model if it was still considered appropriate to pool data.
RESULTS
Seventy potentially relevant trials were evaluated (fig 1
shows the numbers of studies evaluated at each stage).

Studies identified (n=174)
Cochrane databases, Medline,
Embase,LILACS, supplementary
search* (November 2007)

Studies considered
for detailed evaluation
(n=70)

Trials included (n=38)†

Trials presented in this report (n=20)
Fluoroquinolones versus:
Chloramphenicol (n=10)
Azithromycin (n=4)
Ceftriaxone (n=3)
Cefixime (n=3)

Studies not eligible (n=104)
Did not include fluoroquinolones (n=91)
Did not include participants with
typhoid or paratyphoid fever (n=9)
Not randomised controlled trials (n=4)
Trials not included (n=32)†
Not or quasi-randomised (n=15)
Miscellaneous reasons (n=10)‡
Duplicate publications (n=3)
Full text not retrievable (n=2)
Ongoing trials (n=2)
Trials not presented (n=18)†§
Comparing:
Different fluoroquinolone durations (n=8)
Different fluoroquinolones (n=4)
Norfloxacin (n=3)
Co-trimoxazole (n=2)
Ampicillin/amoxicillin (n=1)

Fig 1 | Studies evaluated at each stage of the meta-analysis. (*Supplementary search includes:
reference lists, authors’ files, contacting experts, selected conference proceedings, on-going
trial register. †See Cochrane review49 for further details or analyses. ‡Includes sample size <5,
comparing different formulations/routes of same fluoroqinolone, not enough information
presented in published report. §Trials contributing to more than 1 category counted only once.)
page 4 of 11

Details of the excluded studies and the reasons for
exclusion are available. 49 We excluded trials using
norfloxacin 60-62 since this is not recommended for
treating enteric fever because of its low oral
bioavailability. 10 We included 20 trials in the present
analysis—fluoroquinolones were compared with
chloramphenicol (10 trials), 63-72 ceftriaxone (three
trials), 73-75 cefixime (three trials), 39 76 77 and azithromycin (four trials). 40 78-80
Study characteristics and methodological quality
The table details the trials’ characteristics. Only three
recruited children exclusively or predominantly. 40 77 80
Sample sizes were small (ranging from 26 63 to 285 40).
Duration of fluoroquinolone treatment ranged from
three days 72 to 15 days. 66 70 Twelve trials had adequate
methods of randomisation, 39 40 66 70-72 74 75 77-80 10 of which
had adequate allocation concealment.39 40 71 72 74 75 77-80
Three were “double blinded.” 63-65 Final follow-up of
confirmed cases was adequate in 13. 40 63-66 68-73 76 78 Definitions and time points of measurements for outcomes
such as clinical and microbiological failure showed considerable variations. 49
Comparisons involving adults
Fluoroquinolone versus chloramphenicol
Three of the 10 included trials did not clarify the proportion of multidrug resistant strains.65 67 69 Multidrug
resistant strains were absent in all other trials, except
one.72 One trial had no isolates with nalidixic acid
resistance72—the others did not report this information.
The meta-analysis showed no significant differences
between fluoroquinolones and chloramphenicol for
clinical failure (odds ratio 0.65 (95% confidence interval 0.25 to 1.72), n=594, nine trials), but confidence
intervals were wide (fig 2). The results were of borderline significance in favour of fluoroquinolones for
microbiological failure (0.43 (0.18 to 1.03), n=378, six
trials). The odds of clinical relapse were reduced significantly, by 86%, with fluoroquinolones (0.14 (0.04 to
0.50), n=467, six trials). Fluoroquinolone use was associated with a significantly lower mean fever clearance
time (mean difference −25.93 hours (95% confidence
interval −40.12 to −11.74), n=129, three trials) (see
extra fig A on bmj.com) as well as convalescent faecal
carriage (0.17 (0.04 to 0.70), n=298, three trials). There
was significant heterogeneity (P<0.00001) between the
two trials comparing length of hospitalisation, which
could have been due to differences in fluoroquinolone
treatment durations (3 days v 7 days). A random effects
model showed no differences (−3.13 days (−8.52 to
2.26), n=105, two trials).
Sensitivity analysis (not shown)—When we restricted
the analysis to trials of better methodological quality
(that is, adequate methods of randomisation and
allocation concealment) there was no change in
results for clinical failure (n=105)71 72 or microbiological failure (n=45).71 For relapse, when we excluded
trials which did not clearly define or did not confirm
relapse using cultures, we retained only one trial
BMJ | ONLINE FIRST | bmj.com
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No of events
Study

Fluoroquinolone

Chloramphenicol

Quintero-Perez198863

0/13

1/13

14.5

Gottuzzo 199265

1/48

0/48

4.8

3.06 (0.12 to 77.09)

Morelli 199266

4/106

0/30

7.4

2.68 (0.14 to 51.15)

Yousaf 199267

1/25

2/25

19.2

0.48 (0.04 to 5.65)

Abejar 199368

0/15

0/15

—

Not calculable

Arnold 199369

0/57

1/34

18.6

0.19 (0.01 to 4.90)

Cristiano 199570

0/30

0/30

—

Not calculable

Gasem 200371

1/28

2/27

19.6

0.46 (0.04 to 5.43)

Weight (%)

Odds ratio (95% CI)

Odds ratio (95% CI)

Clinical failure
0.31 (0.01 to 8.30)

Phongmany 200572

0/27

1/23

15.9

0.27 (0.01 to 7.02)

Total

7/349

7/245

100

0.65 (0.25 to 1.72)

Heterogeneity: χ2=2.92, df=6, P=0.82, I2=0%
Test for overall effect Z=0.86, P=0.39

0.001

0.1

1

10

1000

0.001

0.1

1

10

1000

0.001

0.1

1

10

1000

Microbiological failure
Bran 199164

0/51

0/51

—

Not calculable

Yousaf 199267

1/25

3/25

17.9

0.31 (0.03 to 3.16)

Abejar 199368

0/15

1/15

9.0

0.31 (0.01 to 8.28)

69

Arnold 1993

2/57

5/34

37.6

0.21 (0.04 to 1.15)

Cristiano 199570

0/30

0/30

—

Not calculable

Gasem 200371

7/23

8/22

35.4

0.77 (0.22 to 2.65)

10/201

17/177

100

0.43 (0.18 to 1.03)

Total

Heterogeneity: χ2=1.62, df=3, P=0.65, I2=0%
Test for overall effect Z=1.90, P=0.06

Relapse
Gottuzzo 199265

0/47

4/48

27.2

0.10 (0.01 to 1.99)

Morelli 199266

0/106

3/30

33.4

0.04 (0.00 to 0.74)

Abejar 199368

0/15

1/15

9.0

0.31 (0.01 to 8.28)

69

Arnold 1993

1/57

2/34

15.2

0.29 (0.02 to 3.28)

Cristiano 199570

0/30

2/30

15.2

0.19 (0.01 to 4.06)

Gasem 200371

0/28

0/27

—

Not calculable

1/283

12/184

100

0.14 (0.04 to 0.50)

Total

Heterogeneity: χ2=1.39, df=4,=0.85, I2=0%
Test for overall effect Z=3.04, P=0.002

Favours fluoroquinolone

Favours chloramphenicol

Fig 2 | Forest plots for trials of fluoroquinolones versus chloramphenicol for treating enteric fever in adult inpatients. Details of studies reporting proportion of
multidrug resistant and nalidixic acid resistant strains are in text. See Cochrane review49 for stratifications.

(n=91)69 with blood culture confirmed relapses and
did not find any difference between fluoroquinolones
and chloramphenicol, although confidence intervals
were wide. The only methodologically adequate trial
(n=55)71 did not report any clinical relapses during
hospitalisation, without longer follow-up. Fever
clearance times were significantly lower with fluoroquinolone use (−27.56 hours (−43.38 to −11.75),
n=103).71 72 Both trials reporting length of hospital
stay were of adequate methodological quality; there
were no data for convalescent faecal carriage from
these trials.
BMJ | ONLINE FIRST | bmj.com

Funnel plots—The number of trials (4 to 7) in included
funnel plots for outcomes clinical failure, microbiological failure, and relapse was well below the recommended number of trials (10) for meaningful
interpretation. No asymmetry was detected for clinical
failure, but some asymmetry was detected for microbiological failure and relapse.49 (See extra fig B on
bmj.com.)
Fluoroquinolone versus cefixime
One open trial conducted on mainly adult outpatients
presenting to hospital had adequate methods of
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No of events
Study

Fluoroquinolone

Cefixime

Weight (%)

Odds ratio (95% CI)

3/40

14.2

0.13 (0.01 to 2.65)

Odds ratio (95% CI)

Clinical failure
Yu 199876

0/40
39

Pandit 2007

1/88

19/70

85.8

0.03 (0.00 to 0.24)

Total

1/128

22/110

100

0.05 (0.01 to 0.24)

Heterogeneity: χ2=0.63, df=1, P=0.43, I2=0%
Test for overall effect Z=3.66, P<0.001

0.001
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1
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1000

0.001

0.1

1

10

1000

Microbiological failure
Yu 199876

0/40

4/40

72.8

Pandit 200739

0/88

1/70

27.2

0.26 (0.01 to 6.53)

0/128

5/110

100

0.14 (0.02 to 1.23)

Total

0.10 (0.01 to 1.92)

Heterogeneity: χ2=0.19, df=1, P=0.66, I2=0%
Test for overall effect Z=1.77, P=0.08

Favours fluoroquinolone

Favours cefixime

Fig 3 | Forest plots for trials of fluoroquinolones versus cefixime for treating enteric fever in adult outpatients and inpatients. There were no relapses in either
arm in Yu et al 1998.76 Pandit et al 200739 reported 2/87 v 6/51 relapses (odds ratio 0.18 (95% confidence interval 0.03 to 0.91). Details of studies reporting
proportion of nalidixic acid resistant strains are in text.
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randomisation and allocation concealment but inadequate follow-up.39 Community medical auxiliaries conducted home based assessments twice daily and
provided directly observed treatment with study drugs;
all participants were also seen at the hospital on day 10.39
Although nalidixic acid resistance was present, the newer
generation fluoroquinolone used (gatifloxacin) is unaffected by nalidixic acid resistance.39 The other trial on
adult inpatients had unclear methodology, and resistance
data were not extractable.76 The meta-analysis showed a
significant reduction in clinical failure (odds ratio 0.05
(95% confidence interval 0.01 to 0.24), n=238) as well
as relapse in the fluoroquinolone group (0.18 (0.03 to
0.91), n=218) (fig 3). No differences were detected for
microbiological failure (0.14 (0.02 to 1.23), n=238), but
the confidence interval was wide. There was a significant
reduction in fever clearance time with fluoroquinolones
(mean difference −41.69 hours (−54.96 to −28.42),
n=238) (see extra fig A). There were no differences in
convalescent faecal carriers (0.26 (0.01 to 6.50), n=227).

Fluoroquinolones versus azithromycin
Both open trials recruiting adult inpatients, had adequate methods of randomisation and allocation
concealment.78 79 One had adequate follow-up.78
There was a high proportion of nalidixic acid resistant
strains in one (52%),79 but this information was not
reported in the other trial. There were no significant
differences in clinical failure (3.32 (0.63 to 17.43),
n=152), microbiological failure (2.05 (0.18 to 23.44),
n=152), or relapse (6.94 (0.31 to 154.85), n=102),
although the confidence intervals were wide and comparisons lacking in statistical power (see extra fig C on
bmj.com). There were no significant differences in
fever clearance times (−8.95 hours (−20.09 to 2.19),
n=152) (extra fig A) or length of hospital stay
(−0.90 days (−0.32 to 2.12), n=152). There was a significant increase in convalescent faecal carriage with
fluoroquinolone use (21.33 (1.18 to 386), n=133; this
was measured early on days 2-3 after end of
treatment).79

Fluoroquinolones versus ceftriaxone
All three trials recruiting adult inpatients were
open.73-75 Two had adequate methods of randomisation and allocation concealment but inadequate follow-up.74 75 Nalidixic acid resistant strains were
absent in one74 and were not reported in the others.
The meta-analysis showed a significantly lower odds
of clinical failure with fluoroquinolones (0.08 (0.01 to
0.45), n=120), but there was no difference in microbiological failure (0.32 (0.03 to 3.17), n=119) or relapse
(0.34 (0.03 to 3.47), n=81), although confidence intervals were wide (fig 4). Fever clearance time was significantly lower with fluoroquinolones (−101.20 hours
(−129.21 to −73.19), n=76) (see extra fig A). There
were no differences in convalescent faecal carriage
(0.35 (0.01 to 9.08) n=81).

Comparisons involving children
Fluoroquinolone versus cefixime
We found only one open trial recruiting hospitalised
children, with adequate methods of randomisation
and allocation concealment but inadequate followup.77 No child was infected by a nalidixic acid resistant
strain. Reduction in clinical failure was of borderline
significance in favour of fluoroquinolones (0.12 (0.01
to 1.02), n=82). There were no significant differences in
microbiological failure (0.22 (0.01 to 4.74), n=82) or
relapse (0.32 (0.01 to 8.26), n=40). Although a trend
favouring fluoroquinolone can be seen, the confidence
intervals were wide. There was a significant reduction
in fever clearance time (−91.00 hours (−115.89 to
−66.11), n=78) and length of hospital stay with fluoroquinolones (−3 days (−4.53 to −1.47 days), n=81). No
convalescent faecal carriers were reported.
BMJ | ONLINE FIRST | bmj.com
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Fluoroquinolones versus azithromycin
Both open trials on mostly paediatric inpatients, with
adequate methods of randomisation and allocation
concealment, had uniformly high proportions of nalidixic acid resistant strains (98%80 and 96%40 in fluoroquinolone arms). One trial used gatifloxacin,40 which
is active against nalidixic acid resistant strains; we
therefore did not combine these trials in a meta-analysis. With ofloxacin there was a significant increase in
clinical failure (2.67 (1.16 to 6.11), n=125), no significant differences in microbiological failure (0.98 (0.13
to 7.21), n=125), and no relapses at one month followup (<90% participants followed).80 Ofloxacin use significantly increased fever clearance time (57.60 hours
(28.31 to 86.89), n=125) and convalescent faecal carriage (14.64 (1.84 to 116.48), n=124) and a borderline
increase in length of hospitalisation (1.10 days (0.00 to
2.20), n=125). In the trial of gatifloxacin versus azithromycin (n=285) there were no significant differences in clinical or microbiological failure (0.96 (0.30
to 3.06) and 0.64 (0.11 to 3.88)), relapse (6.64 (0.34 to
129.74), n=264), fever clearance time (0.73 hours
(−12.97 to 14.43)), length of hospital stay (0.19 days
(−0.49 to 0.87)), or convalescent faecal carriage (2.89
(0.12 to 71.58), n=268), although confidence intervals
were wide.40

Other outcomes
Complications—There were significantly lower complications with gatifloxacin compared with azithromycin
(0.05 (0.00 to 0.94), n=285).40 No differences were
found in other trials of fluoroquinolones with
chloramphenicol,71 72 ceftriaxone,73-75 cefixime,39 77 or
azithromycin.78-80
Adverse events—There were no differences in non-serious adverse events with azithromycin,40 chloramphenicol,67 68 70-72 or ceftriaxone. 74 The meta-analysis of
trials comparing fluoroquinolone and cefixime
showed significant heterogeneity, and was combined
using a random effects model (3.30 (0.11 to 97.30),
n=238). There were no differences in serious adverse
events with ceftriaxone. 74 75 Other trials either
reported no complications or adverse events in either
arm, or reported events without actual numbers of participants experiencing these events. 49
DISCUSSION
Main findings and limitations
Even though enteric fever most commonly affects children in areas where it is endemic, this review shows the
paucity of evidence supporting the use of fluoroquinolones in this age group from adequately designed randomised controlled trials. Adult inpatients are the
group most studied, although they form only a small
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Fig 4 | Forest plots for trials of fluoroquinolones versus ceftriaxone for treating enteric fever in adult inpatients. Details of studies reporting proportion of
nalidixic acid resistant strains are in text. See Cochrane review49 for stratifications.
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proportion of overall typhoid burden. Even in this subgroup, most trials were small with limited statistical
power and serious methodological limitations.
We did not find any trial comparing fluoroquinolones with chloramphenicol in children, and so cannot
make recommendations specific to this age group. In
trials comparing fluoroquinolones and chloramphenicol in adults data were insufficient to detect significant
differences in clinical or microbiological failure. Any
true treatment difference, if one existed, was obscured
by wide confidence intervals, and the role of chance
cannot be excluded as an explanation for these findings. Microbiological failure, measured at varying
time points, was based on blood cultures, although
one reviewed trial71 also reported bone marrow culture
results for ciprofloxacin compared with chloramphenicol (67% v 100% positive cultures on day 5, P=0.04).
Although this difference was significant, it was smaller
than anticipated since penetration of ciprofloxacin
intracellularly was expected to eradicate a much higher
proportion of S Typhi.71 Data suggest that fluoroquinolones were better than chloramphenicol for reducing
clinical relapse, but most investigators did not define
relapse explicitly and data are lacking for relapse confirmed by culture. The wide confidence intervals produced when we restricted our analyses to trials of
adequate methodological quality underscore the limited evidence available. As well as a lack of explicit
definitions for measured outcomes and variations in
times at which these were measured, resistance data
(multidrug resistant and nalidixic acid resistant) were
not explicitly reported, particularly in older trials.
While data were limited for comparisons of fluoroquinolones and cefixime in children, unblinded comparisons involving adults suggest that fluoroquinolones are
better than cefixime for reducing clinical failure and
relapse and better than ceftriaxone for reducing clinical
failure. The lack of methodological rigour—failure to
conceal allocation by some and failure to use blinding
in all—suggests that these results may have been influenced by selection bias and observer bias and may overestimate the benefit of fluoroquinolones compared with
older antibiotics.51 There were too few trials to ascertain
presence of publication bias using funnel plots. However, some asymmetry observed for microbiological failure and relapse for trials involving chloramphenicol
suggests the possibility of publication bias or failure to
publish smaller studies showing non-significant results.81
Our results thus differ from those of a previous
review, a summary of randomised controlled trials of
enteric fever,11 which found fluoroquinolones to be
superior to chloramphenicol, ceftriaxone, and cefixime for clinical failure and fever clearance times.
Although our data suggest that fluoroquinolones had
significantly lower fever clearance times compared
with chloramphenicol, cefixime, and ceftriaxone, the
analyses of fever clearance times must be interpreted
with caution. Mean fever clearance times often follow a
skewed distribution—although most patients clear
fever quickly, some take much longer times—so
meta-analyses conducted using arithmetic means may
page 8 of 11

not be accurate. The persistence of fever in some
patients despite apparent clearance of S Typhi and S
Paratyphi from the bloodstream has been attributed
to the continued production of pyrogenic
cytokines.82-85 This suggests that time taken to clear
fever may not be an adequate measure of antibiotic
efficacy, and consequently may not be an appropriate
end point in typhoid therapy trials. Some investigators
also did not specify whether clinical failures were
excluded or included in calculations of mean fever
clearance time.
Cost considerations
We could not compare the costs of fluoroquinolone
and other antibiotics because of lack of data from trials.
Although fluoroquinolones may be the least costly
alternative for multidrug resistant enteric fever, this
cost advantage has diminished with increasing numbers of strains resistant to older fluoroquinolones
such as ciprofloxacain and ofloxacin.9 13-38 Newer
fluoroquinolones such as gatifloxacin are effective
against nalidixic acid resistant strains,39 but more evidence of efficacy compared with other antibiotics, tolerance, and safety is required,39 as well as close
monitoring of resistance patterns and check on indiscriminate use. For children, one trial found that ofloxacin performed poorly compared with azithromycin in
patients infected with nalidixic acid resistant strains,80
while data for azithromycin versus gatifloxacin are
limited.40
Applicability
Our results may be applicable only to hospitalised
adults with culture confirmed enteric fever—since
most of the trials enrolled such patients. Hospitalised
patients represent the more severe end of the spectrum
of enteric fever, and adults differ from children in disease presentation, severity, and complications.54-57 In
developing regions most patients with typhoid fever
are children—often managed as outpatients without
confirmation by culture.11 Indeed, rates of hospitalisation of primary care patients for culture confirmed
enteric fever have been under 1% with algorithmbased early recognition and management (Z A Bhutta
et al, unpublished data). The widespread empiric use of
fluoroquinolones is also not generally recommended in
children because of the potential risk of arthropathy.58 59
Future directions and policy implications
Appropriate treatment for enteric fever is a clinical and
public health challenge, with rising levels of drug resistance and limited evidence for use of newer agents, particularly for children. Large, well designed, and
methodologically rigorous trials are needed to compare
fluoroquinolones with first line antibiotics in community or outpatient settings, reflecting practice in low
income countries, with accurate reporting of resistance
data. Long term follow-up and monitoring of adverse
effects are also required. Investigators must standardise
definitions and time points of measurements of
BMJ | ONLINE FIRST | bmj.com
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Fluoroquinolones have been recommended as first line therapy for adults and children with
enteric (typhoid and paratyphoid) fever

8

9

However, evidence supporting their use has not been thoroughly analysed, and resistance to
these agents has spread alarmingly
10

WHAT THIS STUDY ADDS
There is limited evidence from methodologically rigorous, unbiased trials of fluoroquinolones
in enteric fever, particularly in children

11
12
13

outcomes, particularly those of subjective nature, such
as clinical failure. The identification of strains with
reduced susceptibility to fluoroquinolones which do
not exhibit nalidixic acid resistance20 27 indicates the
need for reporting and interpretation of fluoroquinolone minimum inhibitory concentrations. In addition
to objective studies of treatment efficacy and cost effectiveness, we need evaluations of algorithmic approaches
to diagnosis and management of prolonged fever in
children in regions where typhoid is endemic.86 Such
protocols will guide antibiotic use and may curb rising
resistance. Surveillance systems for monitoring burden
of disease and resistance patterns are required.87
This paper is based on a Cochrane review published in the Cochrane
Library, issue 4, 2008 (see http://www.thecochranelibrary.com/).49 We
thank the Cochrane Infectious Disease Group for its assistance and
guidance. Cochrane reviews are regularly updated as new evidence
emerges and in response to feedback, and the Cochrane Library should
be consulted for the most recent version of the review. The results of a
Cochrane review can be interpreted differently depending on people’s
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